Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGynecological OncologyDiseaseBreast CancerSubgrouptripel negativeICD10C50.-MeSHSequenceKEYNOTE-355: PEMB200/NPAC100, Breast Ca (PID1930) -|- PEMB200, Maint. (PID1931)ChemotherapyChemo-substanceNab-paclitaxelPembrolizumabChemo-substanceNab-paclitaxelPembrolizumabChemo-substanceNab-paclitaxelPembrolizumabChemo-substanceNab-paclitaxelPembrolizumabNo. Substances2 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentionpalliativeRisksAlopeciaAnemia Hb below 8g/dlColitisEmetogenicity (MASCC/ESMO)HyperthyroidismHypothyroidismIncrease AminotransferasesNeutropeniaPneumonitisRash only studiesPublicationAuthorCortes JDiseaselokal fortgeschrittenes, nicht resezierbares oder metastasierendes Mamma-Ca, triple neg., Erstlinie, ECOG 0-1OriginInternational Breast Cancer Center, Vall d'Hebron Institute of Oncology, Barcelona, Spain, KEYNOTE-355Protocols in Revision 1 protocol foundProtocols under revision.Pembrolizumab 200 / Nab-Paclitaxel 100, Breast Cancer (PID1930)